Fulranumab 3 mg

DRUG4 trials

Sponsors

Janssen Research & Development, LLC

Conditions

OsteoarthritisPain

Phase 3

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

CompletedNCT02289716

Janssen Research & Development, LLCOsteoarthritis, Pain

Start: 2015-07-10End: 2016-10-10Updated: 2025-04-29

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

CompletedNCT02301234

Janssen Research & Development, LLCOsteoarthritis, Pain

Start: 2015-03-25End: 2016-09-19Updated: 2017-09-14

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

CompletedNCT02336685

Janssen Research & Development, LLCOsteoarthritis, Pain

Start: 2015-07-07End: 2016-09-16Updated: 2017-10-02

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

CompletedNCT02336698

Janssen Research & Development, LLCOsteoarthritis, Pain

Start: 2015-07-13End: 2016-09-15Updated: 2017-10-02

Related Papers

Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies

Current Medical Research and Opinion2019-08-0718 citations

Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study.

2017-01-0519 citations